What is the 13F Pro Quality Score for CRDF?

13F Pro ranks Cardiff Oncology, Inc. (CRDF) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRDF's current score at https://13fpro.ai/research/CRDF (free sign-up required for the full ranking).

Where does 13F Pro source CRDF data?

All Cardiff Oncology, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cardiff Oncology, Inc. files with the SEC under CIK 1213037. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRDF in?

Cardiff Oncology, Inc. (CRDF) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRDF research updated on 13F Pro?

CRDF's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cardiff Oncology, Inc.(CRDF)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1213037 CRDF stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.8M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CRDF Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cardiff Oncology, Inc. (CRDF), a Healthcare sector company. CRDF is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.8m in revenue. Based on the latest XBRL financial filings (Q1 2026), Cardiff Oncology, Inc. reports quarterly revenue of $41.0K, net income of $-12.3M, free cash flow of $-12.3M. Top institutional holders of CRDF by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, Laurion Capital Management, based on the most recent SEC filings. CRDF trades on the Nasdaq exchange and files with the SEC under CIK 1213037. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRDF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cardiff Oncology, Inc. directly from SEC EDGAR. Cardiff Oncology, Inc.'s 13F Pro composite quality score has ranged between 12 and 21 since 2021, currently 16.9 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q1 2026

$41.0K

Net Income

Q1 2026

$-12.3M

Free Cash Flow

Q1 2026

$-12.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+26.4% YoY

$488.0KFY 2023

FY20 $366.0KFY21 $359.0KFY22 $386.0KFY23 $488.0K

Net Income

-7.1% YoY

$-41.4MFY 2023

FY20 $-19.3MFY21 $-28.3MFY22 $-38.7MFY23 $-41.4M

Operating Income

-13.8% YoY

$-45.4MFY 2023

FY20 $-19.1MFY21 $-28.9MFY22 $-39.9MFY23 $-45.4M

EPS (Diluted)

-4.5% YoY

$-0.93FY 2023

FY20 $-1.08FY21 $-0.73FY22 $-0.89FY23 $-0.93

Total Assets

-29.7% YoY

$81.6MFY 2023

FY20 $134.7MFY21 $149.5MFY22 $116.2MFY23 $81.6M

Total Debt

—FY 2023

FY20 —FY21 —FY22 —FY23 —

Op. Cash Flow

+8.7% YoY

$-30.9MFY 2023

FY20 $-16.3MFY21 $-23.0MFY22 $-33.8MFY23 $-30.9M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$488.0K +26.4%	$386.0K +7.5%	$359.0K -1.9%	$366.0K +49.6%	$244.6K -35.3%	$378.3K
Net Income	$-41.4M -7.1%	$-38.7M -36.8%	$-28.3M -46.5%	$-19.3M -17.6%	$-16.4M +0.3%	$-16.5M
Operating Income	$-45.4M -13.8%	$-39.9M -38.3%	$-28.9M -51.2%	$-19.1M -14.4%	$-16.7M +2.2%	$-17.1M
EPS (Diluted)	$-0.93 -4.5%	$-0.89 -21.9%	$-0.73 +32.4%	$-1.08	—	$-8.26
Total Assets	$81.6M -29.7%	$116.2M -22.3%	$149.5M +11.0%	$134.7M +929.5%	$13.1M -7.7%	$14.2M
Total Debt	—	—	—	—	—	$0.00
Operating Cash Flow	$-30.9M +8.7%	$-33.8M -46.8%	$-23.0M -41.2%	$-16.3M -23.0%	$-13.3M -0.5%	$-13.2M

AI Insight: CRDF Financial Trends

Cardiff Oncology remains pre-revenue with accelerating cash burn in Q1 2026, erasing Q4 2025 progress toward break-even.

• Net loss improved from $12M–$14M (Q2–Q1 2025) to $7M in Q4 2025, but deteriorated to $12M in Q1 2026.

• Operating cash burn worsened to $12M in Q1 2026 from $6M in Q4 2025, reversing four-quarter trend of improvement.

• Equity eroded 40% from $83M (Q4 2024) to $35M (Q1 2026) amid persistent $0M revenue and ongoing losses.

⚠ Equity runway now ~3 quarters at current $12M quarterly burn rate; no debt available to cushion runway extension.

⚠ Q1 2026 losses reversed 4-quarter improvement arc; monitor for program advancement or financing catalyst.

AI Insight: CRDF Ratio Trends

Cardiff Oncology remains deeply unprofitable with deteriorating ROE, signaling continued losses and negative shareholder returns.

• ROE deteriorated sharply to -142.3% in Q1 2026 from -63.6% in Q4 2025, reflecting accelerating losses.

• ROA worsened to unspecified level in Q1 2026; prior quarter at -46.6%, indicating persistent operational destruction.

• ROIC collapsed to -98.2% in Q3 2025 from -69.0% in Q4 2025, eroding invested capital value.

⚠ Q1 2026 ROE hit -142.3%—worst in dataset—suggesting material earnings miss or equity base deterioration.

⚠ No operating margins or net profit margins reported; inability to measure profitability pathway obscures recovery timeline.

Get alerted when CRDF's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cardiff Oncology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRDF

BlackRock, Inc.
$6.4M3,981,387 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.6M2,855,966 sh
Laurion Capital Management LP
$4.3M2,646,738 sh
PFIZER INC
$3.7M2,411,575 sh
ACORN CAPITAL ADVISORS, LLC
$2.9M1,762,084 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.6M1,599,663 sh
FRANKLIN RESOURCES INC
$2.0M1,205,803 sh
STATE STREET CORP
$1.9M1,186,947 sh
BLAIR WILLIAM & CO/IL
$1.5M922,407 sh
FLPUTNAM INVESTMENT MANAGEMENT CO
$964.1K595,127 sh

Fund	Value	Shares
BlackRock, Inc.	$6.4M	3,981,387
VANGUARD CAPITAL MANAGEMENT LLC	$4.6M	2,855,966
Laurion Capital Management LP	$4.3M	2,646,738
PFIZER INC	$3.7M	2,411,575
ACORN CAPITAL ADVISORS, LLC	$2.9M	1,762,084
GEODE CAPITAL MANAGEMENT, LLC	$2.6M	1,599,663
FRANKLIN RESOURCES INC	$2.0M	1,205,803
STATE STREET CORP	$1.9M	1,186,947
BLAIR WILLIAM & CO/IL	$1.5M	922,407
FLPUTNAM INVESTMENT MANAGEMENT CO	$964.1K	595,127

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRDF on your watchlist

Track score changes the day Cardiff Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRDF a good stock to buy?

13F Pro's AI-powered analysis of Cardiff Oncology, Inc. (CRDF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRDF are available on the CRDF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRDF?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRDF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cardiff Oncology, Inc.'s investment landscape.